InsiderTrades

Form 4 for TARS Tarsus Pharmaceuticals, Inc.

Accepted 2026-03-17 00:00:00 ET · period of report 2026-03-15 · accession 0001827672-26-000005 · SEC index · Original document

Summary rows

Aggregated the way they appear in lists: one row per insider, transaction code and security table.

X Filed Traded Ticker Insider Title Type Price Qty Owned ΔOwn Value
D 2026-03-17 2026-03-15 TARS Azamian Bobak R. Pres, CEO, Board COB, Dir M - OptEx — +66.3K 68.0K +3,787% —
DM 2026-03-17 2026-03-15 TARS Azamian Bobak R. Pres, CEO, Board COB, Dir M - OptEx $0.00 -66.3K 44.6K -60% $0

Purchase Sale Sale after option exercise All abbreviations

Every reported transaction

#TableSecurityDateCodeA/DSharesPriceOwned afterOwnExercise / expiryUnderlyingFootnotes
1 Common Common Stock 2026-03-15 M A 66,274 — 68,024 D — — (F1) The shares were issued pursuant to settlement of vested Restricted Stock Units ("RSUs").
2 Derivative Restricted Stock Units 2026-03-15 M D 11,300 $0.00 0 D — · — to — 11,300 Common Stock (F3) Each Restricted Stock Unit represents a contingent right to receive one share of the Company's common stock. (F4) RSUs granted on March 9, 2022, under the Tarsus Pharmaceuticals, Inc. 2020 Stock Plan. 25% of the RSUs vested on March 15th of each of 2023, 2024, 2025 and 2026.
3 Derivative Restricted Stock Units 2026-03-15 M D 16,975 $0.00 16,975 D — · — to — 16,975 Common Stock (F3) Each Restricted Stock Unit represents a contingent right to receive one share of the Company's common stock. (F5) RSUs granted on March 8, 2023, under the Tarsus Pharmaceuticals, Inc. 2020 Stock Plan. 25% of the RSUs will vest on March 15th of each of 2024, 2025, 2026 and 2027, subject to the Reporting Person's continuous service.
4 Derivative Restricted Stock Units 2026-03-15 M D 23,121 $0.00 46,243 D — · — to — 23,121 Common Stock (F3) Each Restricted Stock Unit represents a contingent right to receive one share of the Company's common stock. (F6) RSUs granted on March 7, 2024, under the Tarsus Pharmaceuticals, Inc. 2020 Stock Plan. 25% of the RSUs will vest on March 15th of each of 2025, 2026, 2027 and 2028, subject to the Reporting Person's continuous service.
5 Derivative Restricted Stock Units 2026-03-15 M D 14,878 $0.00 44,634 D — · — to — 14,878 Common Stock (F3) Each Restricted Stock Unit represents a contingent right to receive one share of the Company's common stock. (F7) RSUs granted on March 5, 2025, under the Tarsus Pharmaceuticals, Inc. 2020 Stock Plan. 25% of the RSUs will vest on March 15th of each of 2026, 2027, 2028 and 2029, subject to the Reporting Person's continuous service.